Comparação do efeito antiangiogênico do ranibizumab e do bevacizumab in vitro

• Autor(a) principal: Souto, Alexandre Cupello [UNIFESP]
• Data de Publicação: 2011
• Outros Autores: Maricato, Juliana Terzi [UNIFESP], Denapoli, Priscila Martins Andrade [UNIFESP], Sallum, Juliana Maria Ferraz [UNIFESP], Han, Sang Won [UNIFESP]
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0004-27492011000500006; http://repositorio.unifesp.br/handle/11600/6668
• topic: Choroidal neovascularization; Macular degeneration; Angiogenesis inhibitors; Antibodies, monoclonal; Tomography, optical coherence; Fluorescein angiography; Intravitreal injections; Vitreous body; Neovascularização de coróide; Degeneração macular; Inibidores da angiogênese; Anticorpos monoclonais; Tomografia de coerência óptica; Angiofluoresceinografia; Injeções intravítreas; Corpo vítreo

Purpose: To evaluate the comparative in-vitro antiangiogenic effect of Bevacizumab and Ranibizumab. Methods: Endothelial venous umbilical cells culture (ECV304) cultivated in F12 media with addition of 10% Fetal Bovine Serum, were plaqued and treated with clinically relevant concentrations of Bevacizumab and Ranibizumab just after the scratch done in the middle of the culture (scratch methodology). Measurements of the linear size of the area free of cell proliferation were done 24, 48 and 72 hours after the scratch day point. All the experiments were done in triplicate and statistical analysis were done with T-student test. Results: Inhibitory effect was observed just at the concentrations of 0.5 and 0.7 mg/ml in both drugs. At 0.7 mg/ml, Ranibizumab demonstrated a more potent proliferative inhibitory effect than Bevacizumab. At the same concentration, Ranibizumab was three times more potent than Ranibizumab. Inhibitory effect was observed just in the first 24 hours for both drugs. Conclusion: Ranibizumab demonstrates an increased effect when compared to Bevacizumab and this is related more to the different molar rate of each drug than related to a real better proliferative inhibitory effect.